Servier shared on LinkedIn:
“We’re attending EANS 2026 in Hamburg, one of the largest neurosurgery congresses in Europe! Around 2,500 participants from across the European and international neurosurgical community
Join us at Booth 23 and don’t miss our symposium, where we will share insights and engage with healthcare professionals dedicated to advancing neuroscience and patient care.
At Servier, we’re committed to fighting cancer and becoming an innovative player developing targeted therapies to treat cancer, such as glioma, cholangiocarcinoma, and colorectal cancer. Today, close to 70% of our R and D investment is dedicated to oncology research, reflecting our determination to bring new therapeutic options to patients who need them most.
Learn more about our commitment to oncology.”
Read more articles about Servier on OncoDaily.
